4.5 Article

Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial

期刊

JOURNAL OF ALZHEIMERS DISEASE
卷 88, 期 1, 页码 75-95

出版社

IOS PRESS
DOI: 10.3233/JAD-220148

关键词

Bifidobacterium; brain atrophy; cognitive function; mild cognitive impairment; probiotics

资金

  1. JSPS KAKENHI [JP19K11724]

向作者/读者索取更多资源

This study investigated the effect of the probiotic strain Bifidobacterium breve MCC1274 (A1) on cognitive function and brain atrophy in older patients with mild cognitive impairment (MCI). The results showed that probiotics supplementation improved some aspects of cognitive function and slowed down the progression of brain atrophy, especially in patients with significant atrophy. However, there were no significant changes in the overall composition of the gut microbiota.
Background: Probiotics have been reported to ameliorate cognitive impairment. Objective: We investigated the effect of the probiotic strain Bifidobacterium breve MCC1274 (A1) in enhancing cognition and preventing brain atrophy of older patients with mild cognitive impairment (MCI). Methods: In this RCT, 130 patients aged from 65 to 88 years old with suspected MCI received once daily either probiotic (B. breve MCC1274, 2x10(10) CFU) or placebo for 24 weeks. Cognitive functions were assessed by ADAS-Jcog and MMSE tests. Participants underwent MRI to determine brain atrophy changes using Voxel-based Specific Regional Analysis System for Alzheimer's disease (VSRAD). Fecal samples were collected for the analysis of gut microbiota composition. Results: Analysis was performed on 115 participants as the full analysis set (probiotic 55, placebo 60). ADAS-Jcog subscale orientation was significantly improved compared to placebo at 24 weeks. MMSE subscales orientation in time and writing were significantly improved compared to placebo in the lower baseline MMSE (< 25) subgroup at 24 weeks. VSRAD scores worsened in the placebo group; probiotic supplementation tended to suppress the progression, in particular among those subjects with progressed brain atrophy (VOI Z-score >= 1.0). There were no marked changes in the overall composition of the gut microbiota by the probiotic supplementation. Conclusion: Improvement of cognitive functionwas observed on some subscales scores only likely due to the lower sensitiveness of these tests for MCI subjects. Probiotics consumption for 24 weeks suppressed brain atrophy progression, suggesting that B. breve MCC1274 helps prevent cognitive impairment of MCI subjects.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据